# Modern Immunotherapy in BCG-Unresponsive, BCG-Relapsing and High Risk BCG-Naive Non-Muscle Invasive Urothelial Carcinoma of the Bladder

> **NCT03317158** · PHASE1,PHASE2 · RECRUITING · sponsor: **Noah Hahn, M.D.** · enrollment: 55 (estimated)

## Conditions studied

- Urothelial Carcinoma
- Bladder Cancer

## Interventions

- **DRUG:** Durvalumab (Cohort 1-3)
- **RADIATION:** External Beam Radiotherapy (EBRT)
- **BIOLOGICAL:** Bacillus Calmette-Guérin (BCG)
- **DRUG:** Gemcitabine
- **DRUG:** Docetaxel
- **BIOLOGICAL:** Tremelimumab
- **DRUG:** Durvalumab (Cohort 4/5)
- **OTHER:** To be determined

## Key facts

- **NCT ID:** NCT03317158
- **Lead sponsor:** Noah Hahn, M.D.
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2017-11-21
- **Primary completion:** 2026-12-31
- **Final completion:** 2027-12-31
- **Target enrollment:** 55 (ESTIMATED)
- **Last updated:** 2026-04-15

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03317158

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03317158, "Modern Immunotherapy in BCG-Unresponsive, BCG-Relapsing and High Risk BCG-Naive Non-Muscle Invasive Urothelial Carcinoma of the Bladder". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT03317158. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*